20 April 2009

Contents

Conference reports

• Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART

• Risk factors for adverse pregnancy outcomes in Botswana

• Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery

• Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine

• Covering the nevirapine tail

• Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

• High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana

• Children on HAART do extremely well at South African clinic

• New boosting alternatives to ritonavir: GS-99350 and SPI-452

• Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine

• Effect of tenofovir on abacavir phosphorylation

• Nevirapine: fluconazole and TB treatment

• PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

• Identification of drug interactions in clinical practice

• Effect of substance abuse on ART pharmacokinetics

PK and drug interactions

• Effects of omeprazole on plasma levels of raltegravir

• Interaction study of ketoconazole and ritonavir-boosted saquinavir

• Tipranavir/ritonavir interactions with clarithromycin, fluconazole and rifabutin

• Antiretroviral and statin drug-drug interactions

Guidelines

• US Guidelines on prevention and treatment of opportunistic infections updated (2009)

• BHIVA guidelines for TB/HIV coinfection (2009): online for comment

TB coinfection

• WHO global TB control report highlights that 25% of TB-related deaths occur in HIV-positive people